Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Radiotherapy | Research article

Comparative efficacy of six therapies for Hypopharyngeal and laryngeal neoplasms: a network meta-analysis

Authors: Juan Che, Yanlin Wang, Xiaolin Zhang, Jun Chen

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Hypopharyngeal and laryngeal neoplasms are both fatal and hard to catch in early stages. Yet which treatment is the most efficacious one still remain unanswered. This network meta-analysis (NMA) was conducted to investigate effectiveness of six therapies being utilized in clinical practice nowadays.

Methods

PubMed and Embase were retrieved to synthesize data. Direct and indirect evidence was combined to compare efficacy of treatments. A relative ranking of the six regimens was calculated by the surface under the curve ranking area (SUCRA).

Results

A total of 28 trials with 9109 patients were included in our NMA. Five endpoints investigated included 3/5-year overall survival (3/5-OS), 3/5-year disease free survival (3/5-DFS) and 5-year overall survival rate (5-OSR). In terms of all efficacy outcomes, radiotherapy combined with surgery (RT + S) proved to be better than other therapies while radiotherapy (RT) alone also performed well. Induction chemoradiotherapy (ICRT) was the best regarding 3-DFS (SUCRA = 0.846) while current chemoradiotherapy (CCRT) ranked first in 5-DFS (SUCRA = 0.933) according to SUCRA results. No significant differences were demonstrated in 5-DFS and 5-OSR as shown in the results of NMA.

Conclusions

RT combined with surgery turned out to be optimal therapy of all the outcomes while the efficacy of RT was relatively poorer in the treatment of patients with larynx stage III-IV and hypopharynx stage II-IV. Also, the good performance of CCRT and ICRT in terms of DFS made them as secondary recommended therapies. There is no significant difference between surgery and transoral laser microsurgery (TLM) alone.
Appendix
Available only for authorised users
Literature
1.
Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386–96.CrossRef
2.
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–52.CrossRef
3.
Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685–90.CrossRef
4.
Ghadjar P, Simcock M, Zimmermann F, Betz M, Bodis S, Bernier J, Studer G, Aebersold DM, Swiss Group for Clinical Cancer R. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiother Oncol. 2012;104(2):213–8.CrossRef
5.
Huang G, Luo M, Zhang J, Liu H. Laser surgery versus radiotherapy for T1a glottic carcinoma: a meta-analysis of oncologic outcomes. Acta Otolaryngol. 2017;137(11):1204–9.CrossRef
6.
Wolf GT, Bellile E, Eisbruch A, Urba S, Bradford CR, Peterson L, Prince ME, Teknos TN, Chepeha DB, Hogikyan ND, et al. Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2017;143(4):355–66.CrossRef
7.
Stokes WA, Jones BL, Bhatia S, Oweida AJ, Bowles DW, Raben D, Goddard JA, McDermott JD, Karam SD. A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: a National Cancer Data Base analysis. Cancer. 2017;123(4):600–8.CrossRef
8.
Low TH, Yeh D, Zhang T, Araslanova R, Hammond JA, Palma D, Read N, Venkatesan V, MacNeil SD, Yoo J, et al. Evaluating organ preservation outcome as treatment endpoint for T1aN0 glottic cancer. Laryngoscope. 2017;127(6):1322–7.CrossRef
9.
Peng Z, Li Y, Jin L, Tao X, Cai X, Feng J, Liu R, Zhang Q, Li L. Retrospective analysis of therapeutic effect and prognostic factors on early glottic carcinoma. Photodiagn Photodyn Ther. 2016;15:167–71.CrossRef
10.
Marchiano E, Patel DM, Patel TD, Patel AA, Xue YE, Eloy JA, Baredes S, Park RC. Subglottic squamous cell carcinoma: a population-based study of 889 cases. Otolaryngol Head Neck Surg. 2016;154(2):315–21.CrossRef
11.
De Santis RJ, Poon I, Lee J, Karam I, Enepekides DJ, Higgins KM. Comparison of survival between radiation therapy and trans-oral laser microsurgery for early glottic cancer patients; a retrospective cohort study. J Otolaryngol Head Neck Surg = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale. 2016;45(1):42.
12.
Timmermans AJ, de Gooijer CJ, Hamming-Vrieze O, Hilgers FJ, van den Brekel MW. T3-T4 laryngeal cancer in the Netherlands Cancer institute; 10-year results of the consistent application of an organ-preserving/−sacrificing protocol. Head Neck. 2015;37(10):1495–503.CrossRef
13.
Timme DW, Jonnalagadda S, Patel R, Rao K, Robbins KT. Treatment selection for T3/T4a laryngeal Cancer: Chemoradiation versus primary surgery. Ann Otol Rhinol Laryngol. 2015;124(11):845–51.CrossRef
14.
Li P, Hu W, Zhu Y, Liu J. Treatment and predictive factors in patients with recurrent laryngeal carcinoma: a retrospective study. Oncol Lett. 2015;10(5):3145–52.CrossRef
15.
Grover S, Swisher-McClure S, Mitra N, Li J, Cohen RB, Ahn PH, Lukens JN, Chalian AA, Weinstein GS, O'Malley BW Jr, et al. Total laryngectomy versus larynx preservation for T4a larynx Cancer: patterns of care and survival outcomes. Int J Radiat Oncol Biol Phys. 2015;92(3):594–601.CrossRef
16.
Hsin LJ, Fang TJ, Tsang NM, Chin SC, Yen TC, Li HY, Liao CT, Chen IH. Tumor volumetry as a prognostic factor in the management of T4a laryngeal cancer. Laryngoscope. 2014;124(5):1134–40.CrossRef
17.
Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853–9.CrossRef
18.
Lefebvre JL, Andry G, Chevalier D, Luboinski B, Collette L, Traissac L, de Raucourt D, Langendijk JA. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol. 2012;23(10):2708–14.CrossRef
19.
Patel UA, Howell LK. Local response to chemoradiation in T4 larynx cancer with cartilage invasion. Laryngoscope. 2011;121(1):106–10.CrossRef
20.
Mahler V, Boysen M, Brondbo K. Radiotherapy or CO (2) laser surgery as treatment of T (1a) glottic carcinoma? Eur Arch Otorhinolaryngol. 2010;267(5):743–50.CrossRef
21.
Dinapoli N, Parrilla C, Galli J, Autorino R, Micciche F, Bussu F, Balducci M, D’Alatri L, Marchese R, Rigante M, et al. Multidisciplinary approach in the treatment of T1 glottic cancer. The role of patient preference in a homogenous patient population. Strahlenther Onkolo. 2010;186(11):607–13.CrossRef
22.
Schrijvers ML, van Riel EL, Langendijk JA, Dikkers FG, Schuuring E, van der Wal JE, van der Laan BF. Higher laryngeal preservation rate after CO2 laser surgery compared with radiotherapy in T1a glottic laryngeal carcinoma. Head Neck. 2009;31(6):759–64.CrossRef
23.
Thurnher D, Erovic BM, Frommlet F, Brannath W, Ehrenberger K, Jansen B, Selzer E, Grasl MC. Challenging a dogma--surgery yields superior long-term results for T1a squamous cell carcinoma of the glottic larynx compared to radiotherapy. Eur J Surg Oncol. 2008;34(6):692–8.CrossRef
24.
Boscolo-Rizzo P, Maronato F, Marchiori C, Gava A, Da Mosto MC. Long-term quality of life after total laryngectomy and postoperative radiotherapy versus concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope. 2008;118(2):300–6.CrossRef
25.
Andreadis C, Iliopoulou C, Sidiras T, Boutis A, Diamantopoulos N, Vahtsevanos K, Gennatas K, Mouratidou D. Neoadjuvant chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy for larynx preservation in patients with advanced laryngeal cancer. J BUON. 2007;12(3):341–7.PubMed
26.
Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A, Lemanski C, Bourdin S, Tortochaux J, Peyrade F, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006;64(4):983–94.CrossRef
27.
Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, Stromboni-Luboinski M, Hill C. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34(3):224–8.CrossRef
28.
Beauvillain C, Mahe M, Bourdin S, Peuvrel P, Bergerot P, Riviere A, Vignoud J, Deraucourt D, Wesoluch M. Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas. Laryngoscope. 1997;107(5):648–53.CrossRef
29.
Bryant GP, Poulsen MG, Tripcony L, Dickie GJ. Treatment decisions in T3N0M0 glottic carcinoma. Int J Radiat Oncol Biol Phys. 1995;31(2):285–93.CrossRef
30.
Frank JL, Garb JL, Kay S, McClish DK, Bethke KP, Lind DS, Mellis M, Slomka W, Sismanis A, Neifeld JP. Postoperative radiotherapy improves survival in squamous cell carcinoma of the hypopharynx. Am J Surg. 1994;168(5):476–80.CrossRef
31.
Jones AS, Cook JA, Phillips DE, Soler Lluch E. Treatment of T3 carcinoma of the larynx by surgery or radiotherapy. Clin Otolaryngol Allied Sci. 1992;17(5):433–6.CrossRef
32.
Luo XN, Chen LS, Zhang SY, Lu ZM, Huang Y. Effectiveness of chemotherapy and radiotherapy for laryngeal preservation in advanced laryngeal cancer: a meta-analysis and systematic review. Radiol Med. 2015;120(12):1153–69.CrossRef
33.
Feng Y, Wang B, Wen S. Laser surgery versus radiotherapy for T1-T2N0 glottic cancer: a meta-analysis. ORL J Otorhinolaryngol Relat Spec. 2011;73(6):336–42.CrossRef
34.
Zackrisson B, Mercke C, Strander H, Wennerberg J, Cavallin-Stahl E. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol. 2003;42(5–6):443–61.CrossRef
35.
Mo HL, Li J, Yang X, Zhang F, Xiong JW, Yang ZL, Tan J, Li B. Transoral laser microsurgery versus radiotherapy for T1 glottic carcinoma: a systematic review and meta-analysis. Lasers Med Sci. 2017;32(2):461–7.CrossRef
36.
Zhong A, Xu X, Fan H, Wang L, Niu Y. Transoral laser microsurgery for recurrent laryngeal carcinoma after primary treatment: a systematic review and meta-analysis. J Cancer Res Ther. 2015;11(Suppl 2):C173–8.PubMed
37.
Abdurehim Y, Hua Z, Yasin Y, Xukurhan A, Imam I, Yuqin F. Transoral laser surgery versus radiotherapy: systematic review and meta-analysis for treatment options of T1a glottic cancer. Head and neck. 2012;34(1):23–33.CrossRef
38.
Ma J, Liu Y, Yang X, Zhang CP, Zhang ZY, Zhong LP. Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. World J Surg Oncol. 2013;11:67.CrossRef
39.
Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, Zhong LP. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol. 2012;48(11):1076–84.CrossRef
40.
Saitoh JI, Shirai K, Imaeda M, Musha A, Abe T, Shino M, Takayasu Y, Takahashi K, Chikamatsu K, Nakano T. Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer. Radiat Oncol. 2017;12(1):39.CrossRef
41.
Yuan C, Xu XH, Chen Z. Combination treatment with antiEGFR monoclonal antibodies in advanced nasopharyngeal carcinoma : a meta-analysis. J BUON. 2015;20(6):1510–7.PubMed
42.
Vanderveken OM, Szturz P, Specenier P, Merlano MC, Benasso M, Van Gestel D, Wouters K, Van Laer C, Van den Weyngaert D, Peeters M, et al. Gemcitabine-based Chemoradiation in the treatment of locally advanced head and neck Cancer: systematic review of literature and meta-analysis. Oncologist. 2016;21(1):59–71.CrossRef
Metadata
Title
Comparative efficacy of six therapies for Hypopharyngeal and laryngeal neoplasms: a network meta-analysis
Authors
Juan Che
Yanlin Wang
Xiaolin Zhang
Jun Chen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5412-z

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins

Research article

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Research article

Functional role of SGK3 in PI3K/Pten driven liver tumor development

Research article

Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers

Research article

Factors associated with low adherence to cervical cancer follow-up retest among HPV+/ cytology negative women: a study in programmatic context in a low-income population in Argentina

Research article

Screening antiproliferative drug for breast cancer from bisbenzylisoquinoline alkaloid tetrandrine and fangchinoline derivatives by targeting BLM helicase
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits